Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Cytochrome P450 enzyme polymorphisms and treatment-related ovarian toxicity in patients with SLE

Nature Clinical Practice Rheumatology volume 3, pages 492–493 (2007)Cite this article

boxed-textSingh G et al. (2007) Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. J Rheum 34: 731–733

Women with systemic lupus erythematosus and a specific genetic polymorphism of a cytochrome P450 enzyme (CYP2C19*2) are at decreased risk of developing ovarian toxicity after treatment with cyclophosphamide

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mok CC et al. (1998) Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41: 831–837

    Article  CAS  Google Scholar 

  2. Takada K et al. (2004) Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50: 2202–2210

    Article  CAS  Google Scholar 

  3. Huong DL et al. (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29: 2571–2576

    CAS  PubMed  Google Scholar 

  4. Ioannidis JP et al. (2002) Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 29: 2129–2135

    CAS  PubMed  Google Scholar 

  5. McDermott EM et al. (1996) Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 55: 224–229

    Article  CAS  Google Scholar 

  6. Murray M and Petrovic N (2006) Cytochromes P450: decision-making tools for personalized therapeutics. Curr Opin Mol Ther 8: 480–486

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice. The author would like to thank Prof D Boumpas for his critical comments and suggestions.

Author information

Author notes

  1. School of Medicine, University of Athens, Vass Sophias Avenue 114, Athens 115 21, Greece dvassilop@med.uoa.gr

Authors and Affiliations

  1. D Vassilopoulos is an Assistant Professor of Medicine and Rheumatology in the Department of Internal Medicine at the University of Athens, Greece.,

    Dimitrios Vassilopoulos

Authors
  1. Dimitrios Vassilopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vassilopoulos, D. Cytochrome P450 enzyme polymorphisms and treatment-related ovarian toxicity in patients with SLE. Nat Rev Rheumatol 3, 492–493 (2007). https://doi.org/10.1038/ncprheum0574

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0574

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing